1. Comment on “Adjuvant Therapy in Pancreatic Cancer: A Critical Appraisal”

   • Ross A. Abrams

   Commentary 14 September 2012 Pages: 2481 - 2485

2. Comment on “Adjuvant Therapy in Pancreatic Cancer: A Critical Appraisal”

   • Paula Ghaneh
   • Catrin Tudur-Smith
   • John P. Neoptolemos

   Commentary 14 September 2012 Pages: 2487 - 2490

3. Adjuvant Therapy in Pancreatic Cancer: A Critical Appraisal — The Authors’ Reply

   • Helmut Oettle
   • Peter Neuhaus

   Commentary 14 September 2012 Pages: 2491 - 2493

4. Potential Pharmacological Interventions in Polycystic Kidney Disease

   • Amirali Masoumi
   • Berenice Reed-Gitomer
   • Robert W. Schrier

   Leading Article 14 September 2012 Pages: 2495 - 2510

5. Crohn’s Disease

   • Julián Panés
   • Fernando Gomollón
   • Vilar Nos

   Review Article 14 September 2012 Pages: 2511 - 2537

6. Pharmacotherapy for Oesophagogastric Cancer

   • Christopher Jackson
   • Naureen Starling
   • David Cunningham

   Review Article 14 September 2012 Pages: 2539 - 2556

7. Defining the Role of Insulin Detemir in Basal Insulin Therapy

   • Javier Morales

   Review Article 14 September 2012 Pages: 2557 - 2584

8. Cetuximab

   • Stephanie K. A. Blick
   • Lesley J. Scott

   Adis Drug Evaluation 14 September 2012 Pages: 2585 - 2607

9. Etanercept

   • Sheridan M. Hoy
   • Lesley J. Scott

   Adis Drug Evaluation 14 September 2012 Pages: 2609 - 2633

10. Delayed-Release Multi Matrix System (MMX™) Mesalazine

    • Paul L. McCormack
    • Dean M. Robinson
    • Caroline M. Perry

    Adis Drug Profile 14 September 2012 Pages: 2635 - 2642

11. Delayed-Release Multi Matrix System (MMX™) Mesalazine in Ulcerative Colitis

    • Åke Nilsson

    Adis Drug Profiles 14 September 2012 Pages: 2643 - 2643

12. Delayed-Release Multi Matrix System (MMX™) Mesalazine in Ulcerative Colitis

    • Cosimo Prantera

    Adis Drug Profiles 14 September 2012 Pages: 2643 - 2644

13. Imatinib

    • Sarah A. Cross
    • Katherine A. Lyseng-Williamson

    Adis Drug Profile 14 September 2012 Pages: 2645 - 2654

14. Imatinib in Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia

    • Joseph Brandwein

    Adis Drug Profiles 14 September 2012 Pages: 2655 - 2655

15. Imatinib in Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia

    • Ronan Swords

    Adis Drug Profiles 14 September 2012 Pages: 2655 - 2655

16. Imatinib in Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia

    • Barbara Wassmann

    Adis Drug Profiles 14 September 2012 Pages: 2655 - 2656